Glaukos Corporation
NYSE:GKOSMedical - Devices
-$0.18 today
- Market cap
- $13.80B
- Beta
- 0.81
- P/E (TTM)
- -39.0
- EPS (TTM)
- -$3.26
Volume 1.12M
Average 0.94M
GKOS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Glaukos CorporationNYSE: GKOS
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents rises 13.6% from a year ago
Cash & equivalents stood at $114.49M at the end of Q2 FY2026, up 13.6% from a year earlier and up 9.8% from the prior quarter. Over 3 fiscal years it compounded at -8.8% a year.
Context
- Cash & equivalents amounted to 12.4% of total assets at the end of Q2 FY2026, up 2.2 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +13.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 90.81M USD
- Year-over-year change
- -46.5%
- 4-year CAGR
- -2.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 90.81M | -46.5% |
| FY2024 | 2024-12-31 | 169.63M | +81.5% |
| FY2023 | 2023-12-31 | 93.47M | -21.8% |
| FY2022 | 2022-12-31 | 119.53M | +18.7% |
| FY2021 | 2021-12-31 | 100.71M | — |
Cash & Equivalents vs competitors
How GKOS compares with its peers on the latest reported figures
- GKOS's Jun 2026 cash & equivalents of $114.49M is the 6th highest of the 9 companies compared; the peer median is $185.38M.
- Its year-over-year change of +13.6% is the 4th highest of 8, against a peer median of -8.7%.
- Cash & equivalents amounts to 12.4% of total assets for GKOS, versus a peer median of 28.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.71B | +13.9% | +15.9% | 5.4% | |
| Mar 2026 | $666.7M | +90.7% | +93.1% | 91.0% | |
| Jun 2026 | $367M | +34.9% | +0.3% | 2.6% | |
SGPSpyGlass Pharma, Inc. Common Stock | Mar 2026 | $238.9M | — | — | 92.5% |
| Apr 2026 | $131.86M | -23.8% | +21.0% | 29.2% | |
| Jun 2026 | $114.49M | +13.6% | -8.8% | 12.4% | |
| Mar 2026 | $84.96M | -21.9% | -20.8% | 77.4% | |
| Mar 2026 | $77.71M | -8.7% | +2.1% | 27.0% | |
| Mar 2026 | $17.57M | -37.2% | +19.0% | 5.8% | |
| Peer median (excluding GKOS) | $185.38M | -8.7% | +15.9% | 28.1% | |
Competitors are the stored peer set for GKOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 100.71M | 119.53M | 93.47M | 169.63M | 90.81M |
| Short-term Investments | 313.34M | 233.17M | 201.96M | 149.29M | 187.95M |
| Net Receivables | 33.44M | 36.07M | 39.85M | 60.74M | 108.61M |
| Inventory | 23.01M | 37.84M | 41.99M | 57.68M | 63.56M |
| Other Current Assets | 15.63M | 17.25M | 18.19M | 12.46M | 24.05M |
| Total Current Assets | 486.13M | 443.86M | 395.46M | 449.79M | 474.98M |
| Property, Plant & Equipment (Net) | 146.13M | 166.83M | 174.54M | 169.94M | 184.18M |
| Goodwill | 66.13M | 66.13M | 66.13M | 66.13M | 66.71M |
| Intangible Assets | 332.78M | 307.87M | 282.96M | 263.45M | 141.92M |
| Long-term Investments | 9.42M | 7.08M | 0 | 0 | 3.83M |
| Tax Assets | 79.13M | 71.79M | 0 | 0 | 0 |
| Other Non-current Assets | 9.11M | 10.61M | 21.33M | 25.45M | 21.86M |
| Total Non-current Assets | 642.7M | 630.31M | 544.95M | 524.96M | 418.5M |
| Total Assets | 1.13B | 1.07B | 940.41M | 974.76M | 893.49M |
| Account Payables | 7.33M | 14.4M | 13.44M | 13.03M | 24.62M |
| Short-term Debt | 1.01M | 430K | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 33.81M | 35.83M | 20.59M | 24.87M | 76.65M |
| Total Current Liabilities | 63.36M | 72.36M | 74.01M | 75.13M | 101.28M |
| Long-term Debt | 280.03M | 281.4M | 282.77M | 0 | 35.77M |
| Deferred Tax Liabilities | 86.45M | 79.05M | 7.14M | 6.93M | 441K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 9.49M | 10.28M | 13.75M | 22.37M | (4.03M) |
| Total Non-current Liabilities | 478.32M | 471.8M | 404.63M | 132.7M | 136.06M |
| Total Liabilities | 541.68M | 544.16M | 478.65M | 207.83M | 237.33M |
| Common Stock | 47K | 48K | 49K | 56K | 58K |
| Retained Earnings | (365.21M) | (464.41M) | (599.07M) | (745.44M) | (933.13M) |
| Accumulated OCI | 15K | (2.98M) | 1.17M | 2.62M | 3.3M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 587.15M | 530.01M | 461.77M | 766.93M | 656.16M |
| Total Debt | 383.39M | 382.91M | 383.74M | 103.4M | 139.64M |
| Net Debt | 282.68M | 263.38M | 290.27M | (66.23M) | 48.83M |
Glaukos Corporation
NYSE:GKOS
Intrinsic Alpha fair value
Locked
Current Price
$233.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.